SLAMF7 FPBMC (33f36e)

SLAMF7 FPBMC (also known as CS-1 FPBMC) is an experimental cell-based immunotherapy developed by the University of Virginia for the treatment of relapsed or refractory multiple myeloma. The therapy consists of fresh peripheral blood mononuclear cells (FPBMC) harvested from the patient and subsequently armed ex vivo with an anti-CD3 x anti-SLAMF7 bispecific antibody. This bispecific antibody is designed to simultaneously bind to CD3 on T cells and SLAMF7 (also known as CS1, CRACC, or CD319), a cell surface protein highly expressed on multiple myeloma cells. By bridging the patient's own T cells with the cancer cells, the therapy redirects and activates the immune system to specifically target and eliminate the myeloma cells. A Phase I/II clinical trial (NCT04864522) was registered to evaluate the safety and efficacy of this approach, but the study was withdrawn before enrollment began.

Other names

anti-CD3 x anti-SLAMF7 bispecific antibody armed fresh peripheral blood mononuclear cellsanti-CD-3 x anti-SLAMF7 bispecific antibody armed fresh peripheral blood mononuclear cellsanti-CD 3 x anti-SLAMF7 bispecific antibody armed fresh peripheral blood mononuclear cellsCS1 FPBMCCS-1 FPBMCCS 1 FPBMC